Reviva Pharmaceuticals Holdings Stock Gross Profit
| RVPH Stock | USD 1.14 0.10 8.06% |
Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | -652.3 K | -684.9 K |
Reviva | Gross Profit |
Reviva Pharmaceuticals Holdings Company Gross Profit Analysis
Reviva Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Reviva Pharmaceuticals Gross Profit | (684.9K) |
Most of Reviva Pharmaceuticals' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Reviva Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as Gross Profit. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
Reviva Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.Reviva Pharmaceuticals is currently under evaluation in gross profit category among its peers.
Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| Current Valuation | 32.65 M | ||||
| Shares Outstanding | 33.44 M | ||||
| Shares Owned By Insiders | 14.78 % | ||||
| Shares Owned By Institutions | 30.06 % | ||||
| Number Of Shares Shorted | 5.3 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (10.1 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Short Ratio | 19.04 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 15.2 | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.055 | ||||
| Market Capitalization | 38.12 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.